iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 Weight Loss Drug Market Size, Share Biopharma report 2024: Three's company

Whether you prefer the daily pill or the weekly shot, both options are proven to help you lose weight effectively

The unmet need has driven interest in new agents like glucagon-like peptide-1 (GLP-1) receptor agonists

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, blocking sales of copycat forms of the drug that have made a lot of money for compounding pharmacies

From randomization (week 20) to week 68, treatment with WEGOVY resulted in a statistically significant reduction in body weight compared with placebo (Table 8)

However, skip that dose if it's almost time for the next one